SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2022

SEGMENT REPORTING

Schedule of revenue by reportable segments

	Three Months Ended
(in thousands)	March 31, 2022		March 31, 2021
Net Revenues
Generics, Established Brands, and Other	$	63,185	$	54,521
Rare Disease		1,292		—
Total net revenues	$	64,477	$	54,521
Segment earnings/(loss) before interest, taxes, depreciation and amortization ("EBITDA") and reconciliation to (loss)/income before income taxes
Generics, Established Brands, and Other		14,531		21,839
Rare Disease		(10,448)		(1,278)
Depreciation and amortization		(14,557)		(10,898)
Corporate and other unallocated expenses(1)		(8,721)		(6,618)
Total operating (loss)/income	$	(19,195)	$	3,045
Interest expense, net		(6,613)		(2,454)
Other expense, net		(89)		(515)
(Loss)/income before benefit for income taxes	$	(25,897)	$	76

^{(1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations.}

Schedule of revenue by geographic operations

(in thousands)	Three Months Ended March 31,
Location of Operations	2022		2021
United States	$	63,760	$	53,327
Canada		717		1,194
Total Revenue	$	64,477	$	54,521

Schedule of property and equipment by geographic location

(in thousands)	March 31, 2022		December 31, 2021
United States	$	38,770	$	38,564
Canada		13,685		13,831
India		258		276
Total property and equipment, net	$	52,713	$	52,671